title: Outcome of cervical cancer in Iranian patients according to tumor histology, stage of disease and therapy.
abstract: BACKGROUND
  Cancer of cervix, the second most common cancer of women overall, is a leading cause of cancer death in developing countries. The purpose of this study was to measure outcome of treated cervical cancer cases in Yazd since 2002 to 2009, according to pathology, stage of disease, lymph node involvement and therapy.
  
  
  METHODS
  100 cases were enrolled and survival was determined through phone calls to generate 3 and 5- year-survival rates, evaluated by long-rank test with SPSS software.
  
  
  RESULTS
  Mean age of the patients was 53.6 years, and 3 -year survival was 75.9 %( mean of 59.4 months). In first months, survival was the same in both pathology types, but because of the higher stages of squamous cell carcinomas in comparison with adenocarcinomas, their overall rate was lower. Stage IIB and IIIB survival rates were 90.9% and 30.8%, respectively, and rates with and without lymph node involvement were 64.8% and 80.1%. With para-aortic lymph node involvement, the rate was 85.8% (mean of 65.3 months). In patients who underwent surgery and chemoradiation, the respective figures were 71.6% and 54.9%. Anemic and non-anemic rates were 50% and 78%.
  
  
  CONCLUSIONS
  3-5 year survival of cervical cancer fluctuates in the range of 70 to 93%. The relationship with lymph node involvement is weak. Survival of women receiving chemotherapy was lower than after surgery. Our findings showed an importance of diagnosis in primary stages and surgical resection of pelvic and para-aortic lymph nodes.
authors.affiliation: Shahid Sadoughi University of Medical Science, Yazd, Iran. drkarimi2001@yahoo.com
authors.forename: Mojgan
authors.initials: M
authors.lastname: Karimi Zarchi
authors.forename: Ali
authors.initials: A
authors.lastname: Akhavan
authors.forename: Hossein
authors.initials: H
authors.lastname: Fallahzadeh
authors.forename: Hossien
authors.initials: H
authors.lastname: Gholami
authors.forename: Atefeh
authors.initials: A
authors.lastname: Dehghani
authors.forename: Sorayah
authors.initials: S
authors.lastname: Teimoori
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000740:Anemia / Q000150:complications; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology; D003430:Cross-Sectional Studies; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007492:Iran; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000628:therapy*